LifeSci Capital Initiates Coverage on Celcuity With Outperform Rating, $27 Price Target
A Quick Look at Today's Ratings for Celcuity(CELC.US), With a Forecast Between $23 to $39
A Quick Look at Today's Ratings for Celcuity(CELC.US), With a Forecast Between $23 to $39
Celcuity Analyst Ratings
Analysts Conflicted on These Healthcare Names: Verrica Pharmaceuticals (VRCA), Celcuity (CELC) and Bluebird Bio (BLUE)
Craig-Hallum Maintains Celcuity(CELC.US) With Buy Rating
Craig-Hallum Maintains Celcuity(CELC.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), Celcuity (CELC) and Intuitive Surgical (ISRG)
Celcuity Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Celcuity (CELC) and Icon (ICLR)
Celcuity Analyst Ratings
Stifel Maintains Buy on Celcuity, Maintains $40 Price Target
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Celcuity (CELC) and 89bio (ETNB)
Celcuity Analyst Ratings
Celcuity's Clinical and Financial Momentum Justifies Buy Rating and $24 Price Target
Growth Potential Drives Buy Rating for Celcuity Despite Current Losses
Analysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA), Celcuity (CELC) and ATAI Life Sciences (ATAI)
Celcuity Analyst Ratings
Needham Reiterates Buy on Celcuity, Maintains $24 Price Target
Celcuity Analyst Ratings